Genmab A/s Stock News

DUBLIN--(BUSINESS WIRE)--The "TRAIL Receptor 2 Agonists - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com''s offering. This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further high

Integrated Investment Consultants LLC raised its position in shares of Genmab A/S (NASDAQ:GMAB) by 1.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,564 shares of the companys stock after acquiring an additional 414 shares during the quarter. Integrated Investment Consultants []

Media Release Copenhagen, Denmark, December 13, 2021

Shares of Genmab A/S (NASDAQ:GMAB) gapped down prior to trading on Friday . The stock had previously closed at $39.40, but opened at $38.22. Genmab A/S shares last traded at $38.42, with a volume of 2,901 shares traded. A number of brokerages have commented on GMAB. HC Wainwright restated a “hold” rating and issued a […]

Equities research analysts forecast that Genmab A/S (NASDAQ:GMAB) will report $0.12 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Genmab A/Ss earnings. The highest EPS estimate is $0.18 and the lowest is $0.02. Genmab A/S posted earnings of $0.14 per share during the same quarter last year, []

State Street Corp lifted its stake in shares of Genmab A/S (NASDAQ:GMAB) by 45.9% during the second quarter, Holdings Channel.com reports. The firm owned 28,096 shares of the companys stock after acquiring an additional 8,839 shares during the period. State Street Corps holdings in Genmab A/S were worth $1,147,000 as of its most recent filing []

Wall Street brokerages expect Genmab A/S (NASDAQ:GMAB) to post sales of $406.75 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Genmab A/Ss earnings. The lowest sales estimate is $379.00 million and the highest is $422.25 million. Genmab A/S reported sales of $327.51 million during the same quarter last year, []

Brokerages predict that Genmab A/S (NASDAQ:GMAB) will report sales of $406.75 million for the current quarter, Zacks reports. Four analysts have made estimates for Genmab A/Ss earnings. The highest sales estimate is $422.25 million and the lowest is $379.00 million. Genmab A/S reported sales of $327.51 million during the same quarter last year, which would []

Koshinski Asset Management Inc. purchased a new stake in Genmab A/S (NASDAQ:GMAB) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 1,677 shares of the companys stock, valued at approximately $73,000. A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GMAB. Captrust Financial []

Ellevest Inc. increased its position in Genmab A/S (NASDAQ:GMAB) by 11.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,330 shares of the companys stock after purchasing an additional 666 shares during the quarter. Ellevest Inc.s holdings in Genmab A/S were []

Berenberg Bank began coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research note released on Wednesday morning, Price Targets.com reports. The brokerage issued a sell rating on the stock. GMAB has been the subject of several other research reports. JPMorgan Chase & Co. reissued an overweight rating on shares of Genmab A/S in a []

Morgan Stanley lowered its stake in shares of Genmab A/S (NASDAQ:GMAB) by 33.8% during the second quarter, HoldingsChannel reports. The firm owned 242,496 shares of the companys stock after selling 123,627 shares during the quarter. Morgan Stanleys holdings in Genmab A/S were worth $9,900,000 as of its most recent SEC filing. Several other institutional investors []

Genmab A/S (NASDAQ:GMAB) has received a consensus rating of Hold from the fifteen research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price []

Invesco Ltd. cut its position in Genmab A/S (NASDAQ:GMAB) by 23.2% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 344,823 shares of the companys stock after selling 104,114 shares during the quarter. Invesco Ltd.s holdings in Genmab A/S were worth $14,079,000 as of its most recent SEC filing. Several other institutional investors and []

Level Four Advisory Services LLC purchased a new position in Genmab A/S (NASDAQ:GMAB) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,595 shares of the companys stock, valued at approximately $376,000. Other institutional investors have also recently made changes to []